financetom
Business
financetom
/
Business
/
Hinge Health files for US IPO as healthcare listings gain momentum
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Hinge Health files for US IPO as healthcare listings gain momentum
Mar 10, 2025 3:25 PM

(Reuters) -Hinge Health, which provides digital exercise therapy programs to help people manage and overcome muscle and joint pain, on Monday filed for its long-sought New York initial public offering.

The San Francisco, California-based company, which was valued at $6.2 billion in a 2021 funding round, reported a 33.4% increase in revenue for 2024 and a reduction in net losses, according to its IPO paperwork.

Hinge Health, along with some of its existing shareholders, plans to sell shares in this proposed offering. It had earlier planned to go public in 2022.

The IPO comes despite recent stock market volatility due to uncertainty around U.S. trade policies and adds to the growing momentum for healthcare listings.

Healthcare IPOs on U.S. exchanges raised $7.1 billion in 2024, compared with $2.8 billion a year earlier, according to data compiled by LSEG.

Increasingly sedentary lifestyle and an aging population in the U.S. are expected to boost the demand for physical therapy in coming years.

Revenue rose to $390.4 million in 2024, compared with $292.7 million a year earlier, while net losses shrunk to $11.9 million in the same period from $108.1 million a year earlier.

Founded in 2014 by Daniel Perez and Gabriel Mecklenburg, Hinge Health's platform provides comprehensive musculoskeletal care ranging from acute injury treatment to chronic pain management and post-surgical rehabilitation.

Hinge Health competes against Kaia Health Software, Omada Health, Sword Health Technologies and Vori Health. The company caters to employers such as ride-hailing company Lyft , retailer Target , and automaker GM .

It raised $400 million in 2021 funding round led by investment firms Tiger Global and Coatue Management.

Other major shareholders include venture capital firm Insight Venture Partners, Atomico, 11.2 Capital, and Bessemer Venture Partners.

Morgan Stanley, Barclays and BofA Securities are the lead underwriters for the offering.

Hinge Health, which has tapped 14 banks for the IPO, will list on the New York Stock Exchange under the symbol "HNGE."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved